12:00 AM
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Alemtuzumab: Phase II

Additional follow-up data from 195 patients in the open-label, U.S. and European Phase II CAMMS223 trial showed that a significantly greater proportion of patients treated with alemtuzumab were free of clinically-active disease, defined as relapse-free without a sustained increase in disability as measured by the Expanded Disability Status Scale (EDSS) through 5 years, vs. Rebif interferon beta-1a (65% vs. 27%, p<0.0001). Additionally, 72% of alemtuzumab-treated patients were relapse-free at 5...

Read the full 348 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >